Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C19H37N5O7 |
| Molecular Weight | 447.5264 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 11 / 11 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CN[C@@H]1[C@@H](O)[C@@H](O[C@H]2[C@H](N)C[C@H](N)[C@@H](O[C@H]3OC(CN)=CC[C@H]3N)[C@H]2O)OC[C@]1(C)O
InChI
InChIKey=URWAJWIAIPFPJE-VHLNBGGKSA-N
InChI=1S/C19H37N5O7/c1-19(27)7-28-18(13(26)16(19)24-2)31-15-11(23)5-10(22)14(12(15)25)30-17-9(21)4-3-8(6-20)29-17/h3,9-18,24-27H,4-7,20-23H2,1-2H3/t9-,10+,11-,12-,13-,14-,15+,16-,17-,18-,19+/m1/s1
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/697346Curator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/3839236 | https://www.ncbi.nlm.nih.gov/pubmed/4073862 | https://www.ncbi.nlm.nih.gov/pubmed/3571044
Sources: https://www.ncbi.nlm.nih.gov/pubmed/697346
Curator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/3839236 | https://www.ncbi.nlm.nih.gov/pubmed/4073862 | https://www.ncbi.nlm.nih.gov/pubmed/3571044
Pentisomicin (Sch 21420) is semisynthetic aminoglycosides with marked antibacterial activity. Like many new aminoglycosides prepared by chemical modification or mutational biosynthesis, Pentisomicin was designed either to enhance potency of the parent compound and/or resist enzymatic inactivation. The activity of Pentisomicin was comparable to gentamicin, sisomicin, netilmicin, and tobramycin but greater than amikacin or kanamycin against S. aureus and most genera of Enterobacteriaceae.
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL352 Sources: https://www.ncbi.nlm.nih.gov/pubmed/697346 |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/3839236
5-epi-sisomicin (Pentisomicin) was given as a single 1 mg/kg intramuscular injection to six adult male volunteers.
Route of Administration:
Intramuscular
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/697346
Agar dilution susceptibility tests were performed with N. gonorrhoeae. Serial twofold agar dilution tests were performed with GC agar base (BBL) plus 1% Kellogg defined supplement. A standardized suspension of cells was prepared from an overnight culture on chocolate agar so that inoculation of each test plate with 0.01 ml (calibrated loop) yielded ca. 10^4 CFU/cm2. The MIC was defined as the lowest concentration of Pentisomicin preventing all growth after 24 h of incubation at 37C in 10% C02 in air.
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
65453
Created by
admin on Wed Apr 02 09:43:14 GMT 2025 , Edited by admin on Wed Apr 02 09:43:14 GMT 2025
|
PRIMARY | |||
|
4654
Created by
admin on Wed Apr 02 09:43:14 GMT 2025 , Edited by admin on Wed Apr 02 09:43:14 GMT 2025
|
PRIMARY | |||
|
55870-64-9
Created by
admin on Wed Apr 02 09:43:14 GMT 2025 , Edited by admin on Wed Apr 02 09:43:14 GMT 2025
|
PRIMARY | |||
|
CHEMBL2105403
Created by
admin on Wed Apr 02 09:43:14 GMT 2025 , Edited by admin on Wed Apr 02 09:43:14 GMT 2025
|
PRIMARY | |||
|
100000082515
Created by
admin on Wed Apr 02 09:43:14 GMT 2025 , Edited by admin on Wed Apr 02 09:43:14 GMT 2025
|
PRIMARY | |||
|
C015852
Created by
admin on Wed Apr 02 09:43:14 GMT 2025 , Edited by admin on Wed Apr 02 09:43:14 GMT 2025
|
PRIMARY | |||
|
L5BS6WSR0E
Created by
admin on Wed Apr 02 09:43:14 GMT 2025 , Edited by admin on Wed Apr 02 09:43:14 GMT 2025
|
PRIMARY | |||
|
DTXSID7046887
Created by
admin on Wed Apr 02 09:43:14 GMT 2025 , Edited by admin on Wed Apr 02 09:43:14 GMT 2025
|
PRIMARY | |||
|
SUB09696MIG
Created by
admin on Wed Apr 02 09:43:14 GMT 2025 , Edited by admin on Wed Apr 02 09:43:14 GMT 2025
|
PRIMARY | |||
|
C175840
Created by
admin on Wed Apr 02 09:43:14 GMT 2025 , Edited by admin on Wed Apr 02 09:43:14 GMT 2025
|
PRIMARY |
ACTIVE MOIETY